Zuclopenthixol decanoate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329631

CAS#: 64053-00-5

Description: Zuclopenthixol decanoate is an anti-schizophrenia drug. Zuclopenthixol decanoate prevented or postponed relapses when compared to other depots (NNT 8, CI 5-53).

Price and Availability




Zuclopenthixol decanoate is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 329631
Name: Zuclopenthixol decanoate
CAS#: 64053-00-5
Chemical Formula: C32H43ClN2O2S
Exact Mass: 554.2734
Molecular Weight: 555.218
Elemental Analysis: C, 69.23; H, 7.81; Cl, 6.38; N, 5.05; O, 5.76; S, 5.77

Related CAS #: 58045-23-1 (HCl)   53772-83-1 (free base)   85721-05-7 (acetate)   64053-00-5 (decanoate)  

Synonym: Zuclopenthixol decanoate, Zuclopenthixol, Zuclopenthixol HCl

IUPAC/Chemical Name: Decanoic acid, 2-(4-(3-(2-chloro-9H-thioxanthen-9-ylidene)propyl)-1-piperazinyl)ethyl ester, (Z)-


InChi Code: InChI=1S/C32H43ClN2O2S/c1-2-3-4-5-6-7-8-15-32(36)37-24-23-35-21-19-34(20-22-35)18-11-13-27-28-12-9-10-14-30(28)38-31-17-16-26(33)25-29(27)31/h9-10,12-14,16-17,25H,2-8,11,15,18-24H2,1H3/b27-13-


Technical Data

White to off-white solid powder.

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016 Feb;6(1):22-32. doi: 10.1177/2045125315623168. PubMed PMID: 26913175; PubMed Central PMCID: PMC4749742.

2: Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of long-acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016 Apr;6(2):66-76. doi: 10.1177/2045125315623584. Epub 2016 Jan 6. PubMed PMID: 27141289; PubMed Central PMCID: PMC4837966.

3: Lacey M, Jayaram MB. Zuclopenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010598. doi: 10.1002/14651858.CD010598.pub2. Review. PubMed PMID: 26624987.

4: Janjić V, Milovanović DR, Zecević DR, Loncar D, Laban O, Stepanović M, Varjaric M, Obradović S, Dejanović SD, Janković S. Zuclopenthixol decanoate in pregnancy: successful outcomes in two consecutive offsprings of the same mother. Vojnosanit Pregl. 2013 May;70(5):526-9. PubMed PMID: 23789295.

5: Poulsen JH, Olesen OV, Larsen NE. Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Ther Drug Monit. 1994 Apr;16(2):155-9. PubMed PMID: 8009563.

6: Martyns-Yellowe IS. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry. West Afr J Med. 1993 Apr-Jun;12(2):110-3. PubMed PMID: 8104468.

7: Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000;(2):CD001164. Review. PubMed PMID: 10796607.

8: Viala A, Ba B, Durand A, Gouezo F, Hou N, Jørgensen A. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl). 1988;94(3):293-7. PubMed PMID: 2895936.

9: Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol. 2014;9(3):310-7. Review. PubMed PMID: 23343447.

10: Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Mølbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand. 1991 Jul;84(1):14-21. PubMed PMID: 1681680.

11: Izmeth MG, Khan SY, Kumarajeewa DI, Shivanathan S, Veall RM, Wiley YV. Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients. Pharmatherapeutica. 1988;5(4):217-27. PubMed PMID: 2902642.

12: Jaanson P, Marandi T, Kiivet RA, Vasar V, Vään S, Svensson JO, Dahl ML. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl). 2002 Jun;162(1):67-73. Epub 2002 Apr 20. PubMed PMID: 12107620.

13: Walker CA. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients. Pharmatherapeutica. 1983;3(5):289-93. PubMed PMID: 6133287.

14: Jørgensen A, Aaes-Jørgensen T, Gravem A, Amthor KF, Dencker SJ, Rosell I, Baastrup PC, Buckhave J, Gram LF. Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology (Berl). 1985;87(3):364-7. PubMed PMID: 2867572.

15: Kazi HA. An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica. 1986;4(9):555-60. PubMed PMID: 3763650.

16: Solgaard T, Kistrup K, Aaes-Jørgensen T, Gerlach J. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels. Pharmacopsychiatry. 1994 May;27(3):119-23. PubMed PMID: 8078952.

17: Aaes-Jørgensen T. Pharmacokinetics of three different injectable zuclopenthixol preparations. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(1-2):77-85. PubMed PMID: 2568662.

18: Barry SJ, Gaughan TM, Hunter R. Schizophrenia. BMJ Clin Evid. 2012 Jun 28;2012. pii: 1007. Review. PubMed PMID: 23870705; PubMed Central PMCID: PMC3385413.

19: Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015 May;41(3):627-36. doi: 10.1093/schbul/sbu128. Epub 2014 Sep 1. PubMed PMID: 25180312; PubMed Central PMCID: PMC4393684.

20: Szukalski B, Lipska B, Welbel L, Nurowska K. Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology (Berl). 1986;89(4):428-31. PubMed PMID: 2875481.